Your browser doesn't support javascript.
loading
Antifungal and anti-inflammatory potential of eschweilenol C-rich fraction derived from Terminalia fagifolia Mart.
Rodrigues de Araújo, Alyne; Iles, Bruno; de Melo Nogueira, Kerolayne; Dias, Jhones do Nascimento; Plácido, Alexandra; Rodrigues, Artur; Albuquerque, Patrícia; Silva-Pereira, Ildinete; Socodatto, Renato; Portugal, Camila C; Relvas, João B; Costa Véras, Leiz Maria; Dalmatti Alves Lima, Filipe Camargo; Batagin-Neto, Augusto; Rolim Medeiros, Jand-Venes; Moreira Nunes, Paulo Humberto; Eaton, Peter; de Souza de Almeida Leite, José Roberto.
Afiliación
  • Rodrigues de Araújo A; The Northeast Biotechnology Network, RENORBIO, Federal University of Piaui, Teresina, PI, Brazil.
  • Iles B; Biotechnology and Biodiversity Center Research, Biotec, Federal University of Piaui, Parnaíba, Piaui, Brazil.
  • de Melo Nogueira K; Biotechnology and Biodiversity Center Research, Biotec, Federal University of Piaui, Parnaíba, Piaui, Brazil.
  • Dias JDN; Laboratory of Molecular Biology of Dimorphic and Pathogenic Fungi, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
  • Plácido A; Glial Cell Biology Laboratory, Institute for Research and Innovation in Health, i3S, University of Porto, Porto, Portugal; Bioprospectum, Lda, UPTEC, Porto, Portugal.
  • Rodrigues A; Glial Cell Biology Laboratory, Institute for Research and Innovation in Health, i3S, University of Porto, Porto, Portugal.
  • Albuquerque P; Laboratory of Molecular Biology of Dimorphic and Pathogenic Fungi, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
  • Silva-Pereira I; Laboratory of Molecular Biology of Dimorphic and Pathogenic Fungi, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
  • Socodatto R; Glial Cell Biology Laboratory, Institute for Research and Innovation in Health, i3S, University of Porto, Porto, Portugal.
  • Portugal CC; Glial Cell Biology Laboratory, Institute for Research and Innovation in Health, i3S, University of Porto, Porto, Portugal.
  • Relvas JB; Glial Cell Biology Laboratory, Institute for Research and Innovation in Health, i3S, University of Porto, Porto, Portugal.
  • Costa Véras LM; Biotechnology and Biodiversity Center Research, Biotec, Federal University of Piaui, Parnaíba, Piaui, Brazil.
  • Dalmatti Alves Lima FC; Federal Institute of Education, Science and Technology of São Paulo, Campus Matão, Matão, Brazil.
  • Batagin-Neto A; São Paulo State Universit, UNESP, Campus of Itapeva, Itapeva, Brazil.
  • Rolim Medeiros JV; The Northeast Biotechnology Network, RENORBIO, Federal University of Piaui, Teresina, PI, Brazil.
  • Moreira Nunes PH; Medicinal Plants Research Center, NPPM, Federal University of Piaui, Teresina, Piaui, Brazil.
  • Eaton P; LAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences of the University of Porto, Porto, Portugal.
  • de Souza de Almeida Leite JR; The Northeast Biotechnology Network, RENORBIO, Federal University of Piaui, Teresina, PI, Brazil; Center for Research in Applied Morphology and Immunology, NuPMIA, University of Brasilia, Brasilia, Brazil. Electronic address: jrsaleite@gmail.com.
J Ethnopharmacol ; 240: 111941, 2019 Aug 10.
Article en En | MEDLINE | ID: mdl-31100435
ETHNOPHARMACOLOGICAL RELEVANCE: Folk knowledge transmitted between generations allows traditional populations to maintain the use of medicinal plants for the treatment of several diseases. In this context, the species Terminalia fagifolia Mart., native to Brazil, is used for the treatment of chronic and infectious diseases. Plants rich in secondary metabolites, such as this species and their derivatives, may represent therapeutic alternatives for the treatment of diseases that reduce the quality of life of people. AIM OF THE STUDY: The aim of this study was to evaluate the antifungal and anti-inflammatory potential of aqueous fraction from ethanolic extract of T. fagifolia, with in silico study of the major compound of the fraction. MATERIAL AND METHODS: The phytochemical study of the aqueous fraction was performed by HPLC, LC/MS and NMR. The antifungal activity was evaluated against yeasts, by determination of the minimum inhibitory concentration and minimum fungicidal concentration. The effect on Candida albicans was analyzed by AFM. The antibiofilm potential against biofilms of C. albicans was also tested. The anti-inflammatory potential of the aqueous fraction was evaluated in vivo by the carrageenan-induced paw edema and peritonitis. A microglial model of LPS-induced neuroinflammation was also studied. Further insights on the activation mechanism were studied using quantum chemistry computer simulations. Toxicity was evaluated in the Galleria mellonella and human erythrocytes models. RESULTS: Eschweilenol C was identified as the major constituent of the aqueous fraction of the ethanolic extract of T. fagifolia. The aqueous fraction was active against all Candida strains used (sensitive and resistant to Fluconazole) with MICs ranging from 1000 to 0.4 µg/mL. By AFM it was possible to observe morphological alterations in treated Candida cells. The fraction significantly (p < 0.05) inhibited paw edema and decreased levels of malondialdehyde induced by carrageenan. In a microglial cell model, aqueous fraction demonstrated the ability to inhibit NF-κB after induction with lipopolysaccharide. The theoretical studies showed structural similarity between eschweilenol C and indomethacin and an excellent antioxidant potential. The aqueous fraction did not present toxicity in the studied models. CONCLUSION: The results indicate that the aqueous fraction of T. fagifolia has potential for biomedical applications with low toxicity. This finding can be attributed to the predominance of eschweilenol C in the aqueous fraction.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Extractos Vegetales / Terminalia / Ácido Elágico / Compuestos Heterocíclicos de 4 o más Anillos / Antiinflamatorios / Antifúngicos Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Animals / Female / Humans / Male Idioma: En Revista: J Ethnopharmacol Año: 2019 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Extractos Vegetales / Terminalia / Ácido Elágico / Compuestos Heterocíclicos de 4 o más Anillos / Antiinflamatorios / Antifúngicos Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Animals / Female / Humans / Male Idioma: En Revista: J Ethnopharmacol Año: 2019 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Irlanda